sotrovimab

AssetAlso called VIR-7831, sotrovimab, GSK-4182136, Xevudy

Monoclonal antibody engineered for immune engagement.

Stage
Phase 3, no development reported
Modality
Antibody
Target
S
1
Indication
2
Trials
2
Developers

No development reported since July 2023. Last activity: Trial NCT05305651 completed. clinicaltrials.gov

Indications

1

In the full profile

  • Target and mechanism1
  • Owner and partners6
  • Trials2
  • Evidence for its targets1
  • Competitors11
  • Signals4

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets